60 Degrees Pharmaceuticals (SXTP) Amortization of Deferred Charges (2023 - 2024)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Amortization of Deferred Charges of $13517.0 for Q1 2024, down 57.44% year-over-year from $31757.0 in Q2 2023, and down 45.08% quarter-over-quarter from $24613.0 in Q2 2023.
60 Degrees Pharmaceuticals (SXTP) Amortization of Deferred Charges (2023 - 2024) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Amortization of Deferred Charges for 2 consecutive years, with $13517.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Amortization of Deferred Charges fell 57.44% year-over-year to $13517.0; the TTM figure through Dec 2024 stood at $13517.0 (changed N/A YoY), while the FY2024 annual figure was $13517.0, down 72.99% from the prior year.
- Amortization of Deferred Charges eased to $13517.0 in Q1 2024 per SXTP's latest filing, from $24613.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $31757.0 in Q1 2023 and bottomed at $13517.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 13,517.00 |
| Mar 31, 2024 | 13,517.00 |
| Jun 30, 2023 | 24,613.00 |
| Jun 30, 2023 | 24,613.00 |
| Mar 31, 2023 | 31,757.00 |
| Mar 31, 2023 | 31,757.00 |